Eli Lilly’s (NYSE:LLY) released study results on Monday that showed the long-term efficacy of mirikizumab, marketed under the ...

After both receiving FDA approval in UC, J&J and Eli Lilly are racing for their IL-23 inhibitors to get the green light in ...

Eli Lilly and Johnson & Johnson are seeking label expansions for Omvoh and Tremfya, respectively, in Crohn’s disease ...

Stelara is one of the most successful Crohn’s therapies, generating $10.8bn last year, Lilly hopes to introduce Omvoh as its ...

Eli Lilly announced that mirikizumab achieved long-term remission in Phase 3 IBD studies, showing promise for ulcerative ...

When stacked up against Johnson & Johnson’s Stelara, Eli Lilly's Omvoh prompted histologic responses in more patients with moderately to severely active Crohn's disease, regardless of biologic ...

Eli Lilly has thrown its weight behind a cause beyond the traditional remit of pharma companies. | Eli Lilly has thrown its ...

Lilly said the new drug – which will be sold under the Omvoh brand – will be launched in the coming weeks. It has already been approved under the same trade name in Europe and Japan ...

Over the last 3 months, EPS estimates have seen 0 upward revisions and 13 downward. Revenue estimates have seen 16 upward ...

In June, AbbVie’s Skyrizi was approved for treating moderately to severely active UC in adults, making it the second IL-23 inhibitor to gain approval, following Eli Lilly's Omvoh. Earlier this ...

Eli Lilly has released histological data from the Phase III VIVID-1 trial showing that its Crohn’s disease therapy Omvoh (mirikizumab) was superior to Johnson & Johnson’s (J&J) Stelara ...